MNKD (mannkindcorp.com) Market Value to Book Value Ratio

Official company branding of MannKind Corp (MNKD)

MannKind Corporation (MNKD) is an innovator in dry powder molecular engineering that developed the unique Technosphere delivery system. By customizing therapies for orphan diseases, MannKind Corporation (MNKD) occupies a specialized niche, avoiding price wars with industry behemoths. This chart of the company's price action on the GURU.Markets platform shows a level of -15.51. The business's success relies on patent protection and physician recognition of inhaled insulin.

MNKD Afrezza: Market Value to Book Value in the range 07/04/2022 - 10/29/2026

Financial and market metric breakdowns for MannKind Corp (MNKD)

- price and consensus price forecast:
Stock Price MannKind Corporation|MNKD - Broker Consensus Forecast
- market capitalization data:
Market Value MannKind Corp.|MNKD - Full Business Value
- book capitalization data:
Book Value per Share MannKind|MNKD - Accounting Value of Company|Market Capitalization to Book Value Ratio mannkindcorp.com|MNKD - Company Total Assets
- debt and liquidity data:
Debt to Equity MannKind Corporation|MNKD - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity MannKind Corp.|MNKD - Company Total Debt|Debts to Book Capitalization MannKind Corp.|MNKD - Company Long-Term Debts|Company Current Liabilities MannKind
Initial company analysis:MannKind Corporation - MNKD
Original product of MannKind Corp.

The monetization of the Technosphere platform and the development of orphan drugs drive the investment attractiveness of MannKind Corporation (MNKD), which is reflected in the market value premium over net assets. The current value of -15.51 in the company's market-to-book ratio demonstrates the market's confidence in future royalties, allowing investors to assess the extent of the premium paid for intellectual capital relative to the book value.

Main competitors

Market Capitalization to Book Value Ratio Haleon plc|KVUE (kenvue.com) - Capitalization to Book Value Ratio|Market Value to Book Value Ratio Verona Pharma VRNA|Market Capitalization to Net Assets Jyong Biotech Limited|Ligand Pharma (LGND) - Market Capitalization to Book Value Ratio|Market Value to Book Value Amneal Corp (AMRX)|Market Capitalization to Book Value Ratio PRGO (Perrigo Company plc)|alvotech.com - Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio Liquidia (LQDA)|GLPG: Market Value to Book Value|ANIP (ANI Pharma) - Market Value to Book Value Ratio|Amphastar Corp (AMPH) - Market Cap to Net Assets Ratio|PCRX (Pacira BioSciences) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio ars-pharma.com (SPRY)|Theravance Biopharma, Inc. (TBPH) - Market Cap to Net Assets Ratio|Market Value to Book Value AQST (Aquestive Therapeutics Inc)|SCPH: Market Value to Book Value Ratio|TECX - Market-to-Book Ratio|Market Cap to Net Assets Ratio Tonix Pharmaceuticals TNXP|SXTC - Market Cap to Book Value Multiple|Market Capitalization to Book Value Ratio eupraxiapharma.com EPRX|BioHarvest Sciences, Inc. (BHST) - Market Value to Book Value|Market Capitalization to Book Value Ratio EXOZ (Invizyne Technologies, Inc.)|Market-to-Book Ratio ORMP|Entera Bio Ltd. (ENTX) - Market Value to Book Value Ratio|Market Value to Book Value HYFT (ipatherapeutics.com)|ABVC BioPharma, Inc. - Market Value to Book Value Ratio|Market Cap to Net Assets Ratio Cumberland Pharmaceuticals Inc CPIX|Quantum BioPharma Limited - Market Capitalization to Book Value Ratio|FGEN: Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio Telomir Pharmaceuticals|RANI (Rani Therapeutics Holdings, Inc.) - Capitalization to Book Value Ratio|Market Value to Book Value Ratio Synergy CHC Corp. (SNYR)|Capitalization to Book Value Ratio RLYB|Market Value to Book Value Ratio LEXX|Market Capitalization to Book Value Ratio Pulmatrix Corporation (PULM)|Market Capitalization to Book Value Ratio PTHL|Aptorum Group Ltd - Market Capitalization to Book Value|Lyra Therapeutics (LYRA) - Market Value to Book Value Ratio|IBO - Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio tnfpharma.com|Capitalization to Book Value Ratio cbdMD|PRFX - Market Cap to Net Assets Ratio|Market Value to Book Value Auris Medical|Market Capitalization to Book Value Ratio LIPO (Lipella Pharmaceuticals, Inc.)|Market Cap to Net Assets Ratio OPTN (OptiNose Inc)|PIRS: Market Value to Book Value Ratio|Procaps Group Corp - Market-to-Book Ratio|Market Value to Book Value Ratio Petros Pharmaceuticals (PTPI)|QLI: Market Value to Book Value|Market Value to Book Value Ratio ACELYRIN (SLRN)|TFFP (TFF Pharmaceuticals Inc.) - Market Capitalization to Net Assets